Chronic Kidney Failure
Conditions
Keywords
Hyperphosphatemia, Phosphate binder
Brief summary
Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb. The purpose of this study is to assess the efficacy of magnesium iron hydroxycarbonate in subjects requiring hemodialysis, compared with a marketed phosphate binder, lanthanum carbonate and placebo.
Detailed description
High levels of phosphate in the blood are linked with serious effects, due to calcium imbalances (high levels of parathyroid hormone (PTH), bone disease, formation of calcium deposites in the body and blood-vessel disease. Current guidelines indicate that blood phosphorous levels should be maintained between 1.13 to 1.78 mmol/L in patients who receive hemodialysis. This is a 2-stage re-randomization design where Stage 1 is a randomized, open label comparison between fermagate and lanthanum carbonate (in a non-inferiority design) and Stage 2 is a randomized double blind comparison between fermagate and placebo (in a superiority design). Objectives at Stage 1: Primary Objective: The primary objective is to establish the efficacy of fermagate by demonstrating the noninferiority (with possible assessment of superiority) of fermagate to lanthanum carbonate in lowering serum phosphate in hemodialysis patients. Secondary objectives: The secondary objectives are to: 1. Determine the safety of fermagate in hemodialysis patients. 2. Compare the effects of fermagate and lanthanum carbonate on measures of mineral metabolism, albumin, pre-albumin and iron status. Objectives at Stage 2: Stage 2 will use patients who complete the 3-month maintenance period of Stage 1 and who were originally randomized to fermagate. Primary Objective: The primary objective is to establish efficacy of fermagate by demonstrating the superiority of fermagate over placebo in lowering serum phosphate in hemodialysis patients. Secondary objectives: The secondary objectives are to: 1. Determine the safety of fermagate in hemodialysis patients. 2. Compare the effects of fermagate and placebo on measures of mineral metabolism, albumin, pre-albumin and iron status.
Interventions
DRUGMagnesium iron hydroxycarbonate
500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
DRUGLanthanum carbonate
750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
DRUGPlacebo
0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
Sponsors
Ineos Healthcare Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Inclusion: Subjects will be considered eligible for entry in the study if they meet all of the following criteria. 1. Male or female, aged ≥18 years. 2. Able to comply with the study procedures and medication. 3. Written informed consent given. 4. On a stable hemodialysis regimen (at least 3x per week) for ≥12 weeks prior to screening. 5. (a) Subject receiving phosphate binder medication(s) at screening, must have been on a stable regimen (dose and medication) for at least 1 month prior to screening and will remain on this regimen until entry into the washout period OR(b) Subjects (i) is not currently receiving any phosphate binding medication at screening (or medication likely to act as a phosphate binder) and (ii) must not have done so for at least one month and (iii) has sustained hyperphosphatemia. 6. Willing to abstain from taking any phosphate binder or oral magnesium-, oral aluminum- or oral iron-containing products and preparations other than the study medication. 7. If required to take \>6000 mg/day of fermagate, the subject will be willing to have at least three meals per day. Specifically, for randomization and inclusion into the treatment period, one of the following criteria must be fulfilled: 8. (a) Is not receiving phosphate binding medication at screen and has a screen serum phosphate value above 3.0 mmol/L (9.3 mg/dL)OR(b) Has a serum phosphate value of ≥1.94 mmol/L (≥6.0 mg/dL) at Washout Visit 2 to 4 or above 3.0 mmol/L (9.3 mg/dL) at visit 1 during washout. Exclusion: Subjects will not be considered eligible for entry in the study if they meet one or more of the following criteria. 1. Participation in any clinical trial using an investigational product or device during the 30 days preceding the Screening Visit. 2. Previous experience of fermagate treatment. 3. A significant history of alcohol, drug or solvent abuse in the opinion of the investigator. 4. Any disease or condition, physical or psychological that, in the opinion of the investigator, would compromise the safety of the subject or the likelihood of achieving reliable results or increase the likelihood of the subject being withdrawn. 5. Laboratory findings at screening which, in the opinion of the investigator, are clinically significant for this subject population. 6. A screen serum magnesium concentration of \>3.0 mg/dL (\>1.25 mmol/L). 7. A known history of hemochromatosis. 8. Subjects receiving either tetracycline or lithium treatment. 9. Subjects receiving nicotinamide (niacinamide) or niacin (nicotinic acid) alone (i.e. not as a constituent of a multivitamin supplementation). 10. A serum ferritin level of ≥1500 ng/mL (≥3370 pmol/L). 11. Non-elective hospitalization in the 4 weeks prior to screening. 12. Female subjects who are of childbearing potential and who are neither surgically sterilized nor using reliable contraceptive methods (hormonal, barrier methods or intrauterine device) or who are lactating or pregnant. 13. Current hypophosphatemia at screening (last 2 consecutive phosphate values of \<2.2 mg/dL \[\<0.7 mmol/L\]). 14. Known history of colorectal malignancy, familial polyposis coli and/or strong family history (in 2 or more first degree relatives) of these terms 15. A QTcF interval of \>560 ms at screen. 16. Known persistent (\>1 month) non compliance (\<70%) with prescribed medication regimens at screen. 17. Current clinically significant intestinal motility disorder. 18. Intestinal motility disorder with current or previous use of lanthanum carbonate. 19. Known intolerance to lanthanum carbonate or any excipients of fermagate or Fosrenol medication. 20. Subjects with inflammatory bowel disease that, in the investigator's opinion, is poorly controlled. 21. Subjects placed under guardianship or tutelage. 22. Subjects previously withdrawn from the study. The above inclusion and
Exclusion criteria
would be the same for all countries except the
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stage 1: Control or not the level of serum phosphate | Within the treatment period |
| Stage 2: Change from treated baseline in mean serum phosphate | At 4 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Stage 1: Change from baseline in mean serum phosphate | End of 3 months treatment in maintenance period |
| Stage 1: Change from baseline in calcium, calcium phosphate product and PTH level | End of 3 months treatment in maintenance period |
| Stage 2: Change from treated baseline in mean serum phosphate | At weeks 1, 2 and 3 |
| Stage 2: Change from treated baseline in Ca, Ca-phosphate product and PTH levels | At the end of weeks 1, 2, 3 and 4 |
Countries
Australia, Brazil, Canada, France, Germany, Malta, New Zealand, Poland, South Africa, Spain, United States
Outcome results
None listed